Late last month, a single case report set the internet on fire. An 80-something woman with a decade of Alzheimer's — largely non-verbal, incontinent, dependent for nearly everything — was given five grams of dried psilocybin mushrooms. Within days, she was speaking spontaneously. Walking better. Dressing herself. Cracking jokes, even.

Cue the headlines. Groundbreaking drug trial. Reverses dementia. Memory restored. Splashy stuff. The kind of story that ricochets across social feeds before anyone reads past the lede.

Here's the thing, though. It wasn't a trial. There was no control group, no blinded raters, no standardised cognitive scales. It was one patient, in one private psychiatric office in São Paulo, observed by people who already knew her. That doesn't make it worthless — case reports have started plenty of legitimate research programs — but it's a long, long way from a treatment. And the psychiatrist who ran the sessions is the first to say so.

What Actually Happened in São Paulo

The patient had been deteriorating for ten years, with the last five marked by what clinicians call hypofunction — flat affect, monosyllabic speech, chronic incontinence, difficulty swallowing, almost no spontaneous communication. Her son approached her psychiatrist, Marcos Lago, with the idea of trying psilocybin. After conversations with the legal guardian and caregivers about risks and the complete absence of evidence in advanced Alzheimer's, they went ahead.

The first session used five grams of dried mushrooms of the so-called Enigma strain. According to the report, she had acute autonomic activation, profuse sweating, suspected hyperthermia, and fell into a prolonged sleep-like state. The next morning, something shifted. She began producing what the authors describe as spontaneous autobiographical speech — she was telling stories from her own life, unprompted.

Over the following weeks, the changes kept stacking up. Bladder control returned. She walked with more confidence. She dressed herself. She made eye contact. A second session, this time at three grams, reportedly brought more expressivity, facial mimicry, even humour. Caregivers — people who'd watched her decline for years — said she was someone they recognised again.

Why the Headlines Got Ahead of the Science

You can see why the press jumped on it. The story is irresistible. A cheap, ancient natural compound bringing a grandmother back from the long fog of Alzheimer's — it writes itself. The problem is that almost every word in those headlines was doing work the underlying paper couldn't support.

It wasn't a clinical trial. It was private psychiatric care, written up afterward. There were no blinded independent assessors. No standardised dementia scales administered at fixed intervals. No control. The dose itself wasn't a dose in the pharmaceutical sense — dried mushrooms vary wildly in potency, and you can't convert mushroom weight into milligrams of psilocybin with any confidence. The patient's improvement, however striking, was reported through clinical observation and caregiver accounts. Those are valuable, but they're not the same thing as evidence in the regulatory sense.

Lago himself is unusually clear about this. He calls the case a research hypothesis, not a treatment recommendation. He resists the framing that any of this proves efficacy. What it does, he argues, is raise a legitimate question worth investigating properly — and that's a much more modest, much more honest claim than what most of the coverage made of it.

Who Is Marcos Lago?

This is where things get interesting, and a bit complicated. Lago is a São Paulo psychiatrist in private practice. He says he has supervised roughly 400 psilocybin sessions involving around 200 adults — a number that would raise eyebrows almost anywhere in the world, and definitely in Brazil, where psilocybin is a proscribed substance under the country's health authority.

Most of those sessions, he says, weren't conventional medical treatment. They happened within what he describes as a philosophical and contemplative framework — meditation, self-knowledge, the study of consciousness. He's also associated with a religious organisation, Associação Cruz de Ankh, which he argues operates within the constitutional protections for freedom of belief and religious practice that Brazil affords.

Is that a clean legal shield? Lago doesn't claim it is. He's careful to draw lines between approved medical treatment, formal research, private psychiatric care, and ceremonial religious practice — categories that, in his words, aren't interchangeable. The Brazilian situation echoes what's happened with ayahuasca, where decades of court rulings carved out space for religious use of the brew. Whether psilocybin will follow a similar path is unsettled.

What This Case Cannot Tell Us

If you're someone watching a parent slip into dementia, or you're considering plant medicine for your own reasons, it's worth being blunt about what this case does and doesn't establish.

• It doesn't prove psilocybin works for Alzheimer's. One patient is one patient. People with dementia have fluctuating symptoms; spontaneous improvements happen.
• It doesn't tell us the right dose. Five grams of dried mushrooms in an 80-year-old with advanced disease is a serious physiological event. The patient had suspected hyperthermia and prolonged unconsciousness — that's not a safety profile anyone should be casual about.
• It doesn't show durability. The follow-up is short, and there's no formal endpoint. We don't know if the gains held.
• It doesn't translate to your situation. The patient was supervised continuously by a psychiatrist with years of experience administering psilocybin, in a controlled setting, with caregivers present.

What it does do is suggest that psilocybin's effects on neuroplasticity, neuroinflammation, and default-mode network activity — the stuff researchers actually study — might be worth examining in dementia populations. That's a real scientific question. It deserves real trials with proper design, not viral tweets.

The Broader Question: Are Psychedelics Useful for Stuck Patterns?

Step back from Alzheimer's for a moment. The reason a case like this captures imagination is that it touches a broader hope: that psychedelics and master plants might unstick things that conventional medicine can't. Addiction. Depression that won't lift. Trauma stored in the body for decades. The default-mode network humming on the same anxious loop year after year.

The evidence for some of these uses is genuinely promising. Psilocybin for treatment-resistant depression has produced striking results in Phase 2 trials. Ibogaine for opioid addiction has decades of underground data and now mounting clinical interest. Ayahuasca's effects on depression and substance use have been studied in religious-use cohorts for years. None of this is magic — the responsible researchers are quick to point out non-responders, adverse events, and the need for psychological support before and after.

But there's a real signal in the noise. People do, sometimes, change in ways they couldn't access through talk therapy or SSRIs alone. The mechanism isn't fully understood. The set, setting, and integration matter enormously. And the people who do best are usually the ones who treated the experience as the start of work, not the end of it.

If You're Considering a Retreat Yourself

For readers thinking about this for their own reasons — not Alzheimer's, but the everyday stuck places that bring most people to plant medicine — a few unglamorous suggestions.

1. Get honest about why. A psychedelic experience won't substitute for a decision you've been avoiding. It might, however, make the decision impossible to keep avoiding.
2. Vet the facilitators. Ask about medical screening, training lineage, what they do in a crisis, how they handle integration. A reputable retreat will answer plainly. A sketchy one will get vague.
3. Take preparation seriously. Diet, sleep, reducing alcohol and stimulants in the weeks before — these matter more than people think.
4. Plan the landing. The week after is often more important than the ceremony. If you don't have a therapist, a coach, or a journaling practice you'll actually use, build one before you go.
5. Mind the medications. SSRIs, MAOIs, certain blood pressure drugs — interactions can be serious. A real facilitator will ask about every pill you take.

None of this is meant to talk you out of anything. Plant medicine has helped a lot of people address things that nothing else touched. It's just that the help tends to come to people who showed up prepared, not to people who showed up looking for a shortcut.

Where This Case Report Leaves Us

The honest read on the São Paulo case is somewhere between the breathless headlines and the dismissive scoff. It's one observation. It's interesting. It probably justifies a properly designed trial in carefully screened patients with mild-to-moderate cognitive impairment, with continuous medical monitoring and standardised outcome measures. It does not justify a wave of families giving five-gram doses of unregulated mushrooms to elderly relatives at home. Please don't.

What Lago seems to want — and what the field actually needs — is the boring, slow, methodical version of this story. Trials. Data. Replications. Honest reporting of the cases that didn't work alongside the ones that did. The interesting thing about psilocybin research right now is that, after decades of prohibition, that boring slow version is finally starting to happen.

If reading all this has left you curious about the broader landscape of plant-medicine work — psilocybin retreats, ayahuasca ceremonies, ibogaine programs — a range of vetted psychedelic and plant-medicine retreats can be browsed on our marketplace here. Whatever you decide, decide it with eyes open.